These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 11594680

  • 1. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F.
    Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
    Kumar R, Semaine W, Johar M, Tyrrell DL, Agrawal B.
    J Med Chem; 2006 Jun 15; 49(12):3693-700. PubMed ID: 16759112
    [Abstract] [Full Text] [Related]

  • 4. Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.
    Srivastav NC, Shakya N, Mak M, Agrawal B, Tyrrell DL, Kumar R.
    J Med Chem; 2010 Oct 14; 53(19):7156-66. PubMed ID: 20857959
    [Abstract] [Full Text] [Related]

  • 5. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF.
    Antivir Chem Chemother; 2001 Oct 14; 12 Suppl 1():67-71. PubMed ID: 11594691
    [Abstract] [Full Text] [Related]

  • 6. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F.
    Antimicrob Agents Chemother; 2006 Mar 14; 50(3):955-61. PubMed ID: 16495257
    [Abstract] [Full Text] [Related]

  • 7. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H.
    J Med Virol; 2006 Mar 14; 78(3):341-52. PubMed ID: 16419116
    [Abstract] [Full Text] [Related]

  • 8. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F.
    Antiviral Res; 2011 Nov 14; 92(2):271-6. PubMed ID: 21871497
    [Abstract] [Full Text] [Related]

  • 9. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.
    J Viral Hepat; 2005 Jul 14; 12(4):364-72. PubMed ID: 15985006
    [Abstract] [Full Text] [Related]

  • 10. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J, Papp I, Csöndes M, Nemesánszky E, Rácz I, Ribiczey P, Telegdy L, Tornai I, Weisz G.
    Orv Hetil; 2003 Jun 22; 144(25):1251-6. PubMed ID: 12901182
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
    Semaine W, Johar M, Tyrrell DL, Kumar R, Agrawal B.
    J Med Chem; 2006 Mar 23; 49(6):2049-54. PubMed ID: 16539393
    [Abstract] [Full Text] [Related]

  • 12. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 13. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A, Locarnini S.
    J Med Virol; 2006 Oct 15; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [Abstract] [Full Text] [Related]

  • 14. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y.
    Clin Gastroenterol Hepatol; 2008 Mar 15; 6(3):268-74. PubMed ID: 18328434
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
    Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Trepo C.
    Antivir Ther; 2009 Mar 15; 14(1):131-5. PubMed ID: 19320247
    [Abstract] [Full Text] [Related]

  • 16. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Ren GL, Fang Y, Ma HH, Lei YF, Wang D, Xu MC, Wang PZ, Huang CX, Nie OH, Sun YT, Bai XF.
    Antivir Ther; 2007 Mar 15; 12(6):865-76. PubMed ID: 17926641
    [Abstract] [Full Text] [Related]

  • 17. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
    Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F.
    Gastroenterology; 2009 Jan 15; 136(1):168-176.e2. PubMed ID: 18996386
    [Abstract] [Full Text] [Related]

  • 18. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S, Warner N.
    Antivir Ther; 2007 Jan 15; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [Abstract] [Full Text] [Related]

  • 19. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J, Ramos B, Toro C, Ríos P, Martínez-Alarcón J, Bottecchia M, Romero M, Garcia-Samaniego J, Soriano V.
    Antivir Ther; 2008 Jan 15; 13(1):97-102. PubMed ID: 18389903
    [Abstract] [Full Text] [Related]

  • 20. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z.
    Med Sci Monit; 2002 Apr 15; 8(4):CR257-62. PubMed ID: 11951067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.